N8 Display PPT

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

1
Company Presentation
Q3 2022

Forward-looking Statements
2
This presentation includes statements that may be forward-looking statements. The words “beli...

The N8 opportunity (summary)
3
Feel good: Saves lives,
reduces overall healthcare
Not just “yet another antimicrobial”
Don...

4
The next pandemic is already here
ANTIMICROBIAL
RESISTANT
INFECTIONS
Modern medicine as we
know it is threatened by
anti...

5
Recent CDC Data shows AMR is rising at an alarming rate
the US Centers for Disease
Control and Prevention and the
World ...

A global focus on AMR escalates the need for
infection prevention
6
sleepy and under-invested to
exciting and important…
O...

7
Confronting Antimicrobial Resistance
FIRST STOP
Hospital Acquired Infection (HAI)
Preventing Infection

N8 is pursuing a critical path to preventing HAIs
8
More than half of HAIs are caused
by fouled medical devices
of HAIs ar...

9
CONFIDENTIAL
CSA-131 Pathogen
-
The CSA molecule’s net positive
charge attracts the negatively-charged
membranes of cert...

10
Significant scientific
community engagement
supported by KOLs, publications,
data & intellectual property
Strategic dis...

The first N8 solution is a patented CSA-coated endotracheal tube (ETT)
Designed to eradicate healthcare-associated infecti...

Patented CeraShield is proven to reduce bacterial colonization by 97%*
Suctioning Group* Control Group* Cerashield Study P...

13
Targeting Canada
Health Canada granted full marketing approval for N8’s CeraShield ETT.
Head of the Canadian Clinical T...

CERASHIELD ETT MARKETING APPROVAL
Canada
Brazil
NO MEDICAL DEVICE REGULATION
Chile
Republic of Georgia
CERASHIELD ETT APPR...

Country / Study Sites Objective Design
Outcomes/
Data Endpoints
Cases/
tubes
22Q3
22Q4
23Q1
23Q2
Republic of
Georgia
COVID...

Country Site
Cases/
tubes
Aug
Sept
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
UAE Prime Hospital Dubai 100
South
Africa
Tygerberg Hos...

17
Platform Patented Technologies

N8 technology has wide potential applicability throughout healthcare
CATHETERS
Airway management
Abscess drains
Biliary st...

N8 Device Development Pipeline (Initial approvals within 12-24 months)
CeraShield® ETT Canada and
Brazil approval, FDA rec...

BioPharma Product Development (24–48 months to clinical testing)
20
* Linh Anh Cat, “The Decade Of The Microbiome.” Forbes...

21
Business Strategy

INDUSTRY- JOINT
DEVELOPMENT
MEDICAL
DEVICE
DEVELOPMENT
BIOPHARMA
PIPELINE
DEVELOPMENT
N8 Biosciences business strategy
22
...

23
INFLECTION POINTS
(Value created to date)
1-2 YEAR ROADMAP
Positioning: Value to date and future (pending) milestones
P...

24
Financials

Valuation Statements
25
Benefitted from
University
sponsored
research to expand
patent portfolio of
licensed products
Nume...

Use of Proceeds – Over the next 12 months.
Perform
multiple OUS
trials and gather
safety data
leading to IND
Pharma – Devi...

27
Leadership

Management Team
28
N8 Biosciences leadership team has
extensive experience in research, development,
and commercializing t...

Management Team
Position Experience
Robert Mitchell CHIEF EXECUTIVE OFFICER Founder RDM Enterprises. CEO N8 Medical, Cora ...

Board of Directors
Position Experience
Jay Golding CHAIRMAN Founder, CEO Hi-Port Industries, Falcon Seaboard, Golding
Brot...

Chief Advisors
Position Experience
Paul Savage PhD SCIENCE AND CHEMISTRY
Professor of Chemistry BYU, Inventor of Ceragenin...

Chief Advisors
Position Experience
Matthew Reed PhD SCIENCE AND CHEMISTRY
Dr. Reed is a pharmacologist, board certified to...

Investment Highlights
33
1 2 3
4 5
Experienced
and proven
leadership team &
external consultants
Broad IP
protecting multi...

34
Appendix

Initial market opportunities excluding US, Europe, China, India
35
Current Current Total Potential Savings Revenue to N8 N...

Medical device regulatory pathway delivers lower risk,
faster time to market than drug solutions
36
MEDICAL DEVICES DRUGS ...

Reimbursement Advantages
37
VALUE BASED PRICING
Get paid based on product’s
performance in preventing infections
and other...

N8 licensed technology heavily patent protected
38
Issuing Body Pending Registered Total
US PTO 12 35 47
European Patent O...

Competition: No viable alternatives to address ETT biofilm formation
39
BACTIGUARD
Swedish Public Company BACTI.B
Market C...

40
Bad news/good news for antibiotic development
THE BAD NEWS
Large Pharma has abandoned development
in favor of more prof...

REGION COUNTRY COMPANY
APAC ANZ, Singapore, Philipines, South Korea
Taiwan
Korea
Japan
Vietnam
India
EMEA Georgia
Saudi Ar...

CSAs mimic and enhance innate immunity, reduce/control inflammation
LL-37 is the natural first line defense against infect...

Typical Endotracheal Tube Example
44
44

N8 is tackling the coming global tsunami of AMR
45
AMR Crisis Projections
MEDICAL ECONOMIC SOCIAL
Entering the Post
Antibi...

Stroke Patients who require mechanical ventilation
are at high risk for VAP
46
Many patients with acute intracerebral hemo...

Stroke patients who require mechanical ventilation
are at high risk for VAP
47
Lioutas V, -A, Marchina S, Caplan L, R, Sel...

Ceragenins are Highly Effective Against Antimicrobial-Resistant Pathogens
Paprocka P, Mańkowska A, Skłodowski K, Król G, W...

Cont…
49
Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM,
Savage PB. Susceptibility of Colistin-Resistant, Gram-
Negat...

Share Slideshare

LinkedIn
Facebook
Twitter

Embed

Size (px)

Show related Slideshows at end

WordPress Shortcode

Link

Share
Email

2024 Trend Updates: What Really Wor... by Search Engine Jou... 1054718 views
Storytelling For The Web: Integrate... by Chiara Aliotta 970719 views
Artificial Intelligence, Data and C... by OECD Directorate ... 905165 views
How to Leverage AI to Boost Employe... by SocialHRCamp 382887 views
2024 State of Marketing Report – by... by Marius Sescu 216911 views
Everything You Need To Know About C... by Expeed Software 234552 views

View on Slideshare

1 of 49 Ad

View on Slideshare

1 of 49 Ad